Founders With the support of. 2 Letters of intent  Individual quotation, then selection by the SAB Validation by the Bureau  Full Application  Individual.

Slides:

Advertisements

Similar presentations

Distinctive characteristics

Advertisements

Use of PMCA for Biochemical Diagnosis of Prion Diseases Claudio Soto, PhD Dept of Neurology, University of Texas Medical Branch and Amprion Inc.

Vaccines and Related Products FDA Advisory Committee Meeting

Removal of Prions by Plasma Fractionation Processes

Bovine Spongiform Encephalopathy (BSE) in Canada Pedro Piccardo, MD Division of Emerging and Transfusion-Transmitted Diseases Office of Blood Research.

® Bovine Derived Products are Safe TSE Advisory Committee Serologicals Corporation February 2004.

1 Donor Deferral / Ineligibility for Time Spent in Saudi Arabia to Reduce Risk of vCJD Transmitted by Blood and Blood Products and by Human Cells, Tissues.

Silvia Maria DOGLIA Nanoparticelle di aggregati proteici DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.

Industry TSE clearance studies for plasma-derived Factor VIII (pdFVIII) Dr. Thomas R. Kreil, Chair, PPTA Pathogen Safety Steering Committee.

Viral Detection By: Douglas Tran.  Past research  States Prion hypothesis and past research of no past viral genetic material detected  States the.

Mouse Prion Protein Domain PrP( ) Andreas Razen Geometric Computations in Molecular Biology 2 May 2007.

The following is an animation demonstrating the effects of prions on neuronal cells. Prions are misfolded proteins which provoke an array of neurodegenerative.

L and D isomers of amino acids. Ionization state as a function of pH.

Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.

Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.

Prion Diseases Microbes and Society Fall What is a Prion? Prion- small proteinaceous infectious particles which resist inactivation by procedures.

Prion biology problem space: Mad cows, itchy sheep and protein structure.

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical.

Pronucleon TM Amplified Misfolded Protein Diagnostic Assay (AMP-D) Kenton L. Lohman, Ph.D. VP Assay Development Adlyfe Inc., Rockville, MD.

Viruses, Viroids, and Prions

Transmissible Spongiform Encephalopathies (TSEs) a.k.a. Prion Diseases Transmissible  can be spread Spongiform  resembling a sponge Encephalopathies.

1 Evaluation of Prion Reduction Filters with a Highly Sensitive Cell Culture-Based Infectivity Assay Evaluation of Prion Reduction Filters with a Highly.

Prions: Proteins Gone Bad

Founders With the support of Results4th Call for Projects NeuroPrion2010 Salzburg.

1 An Introduction to the Viruses. 2 Viral Components All viruses have capsids- protein coats that enclose & protect their nucleic acid Viruses may have.

Prions and Protein Misfolding BICH 107 GENE 105. Kuru Discovered in Papua New Guinea in early 1900's "Trembling with fear" Characterized by headaches,

Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.

Proposed algorithm for approval of human TSE tests in Europe.

Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.

Prion Digestion in the Alimentary Tract Nicholas Toney.

Safety of IVIgG Elspeth McIntosh SNBTS Medical Information and Pharmacovigilance Manager.

12 August 2003 CJD Update Latest facts, figures & findings Jonathan P Clewley TSE Unit, Virus Reference Division, Centre for Infections 20 May 2005.

Laboratory of Cellular Hematology

Thomas R. Kreil, Ph.D. Chair, PPTA Pathogen Safety Steering Committee

1 Laboratory of Bacterial, Parasitic and Unconventional Agents (LBPUA) Research Programs Report to BPAC 13 July 2006 Site Visit by Ad Hoc Review Committee.

WHO Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies World Health Organization 2006 Proceedings of a Consultation.

TSE Clearance Studies for pdFVIII: Study Methods and Clearance Levels TSE Advisory Committee September 18, 2006 Dorothy Scott, M.D. Office of Blood Research.

19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.

18 th Meeting of FDA TSE Advisory Committee: 31 October 2005 Summary FDA Blood Products Advisory Committee 85 th Meeting 03 November 2005 Holiday Inn Gaithersburg.

Prion cell tropism significantly varies among animal species, depending on both the agent strain and host-specific factors. For example, prions show high.

C B E R E R Vostal 10/2005 Labeling Claims for TSE Reduction Studies with Blood Processing Filters Jaro Vostal, M.D., Ph.D. Division of Hematology, OBRR.

TSE Agent Clearance Issues TSE Advisory Committee February 20, 2003 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.

TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.

The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.

Viruses, Viroids, and Prions

Review of Publicly Available Information on TSE Clearance by Steps Used to Manufacture FVIII Products TSE Advisory Committee October 31, 2005 Dorothy Scott,

Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.

TSE Task Force Prion reduction evaluation in the manufacturing of plasma protein therapies Dr. Henry Baron, Chair, PPTA TSE Task Force.

Microbes and Diseases Chapter 02. CREUTZFELDT-JAKOB DISEASE Prion.

Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.

Viruses. 1.What is a virus? 2. nonliving 2. they have an outer layer called a capsid 2. they contain DNA or RNA 3. never both.

Dr. Stuart Reichler Bio 311D. DateSubjectTextbook Chapters Jan 14Introduction, Philosophy of Science 16Strong Inferencearticle on webpage 18, 23Meiosis12,

TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,

Proteolytic Inactivation of prions; a biological solution to TSE decontamination. Dickinson J*, Murdoch H*, Sutton JM*, Crabb, W. D.#, Bott, R#, Penet,

Aya Murakami. Background Transmissible Spongiform Encephalopathies and Prion Other for TSEs CWD Distribution in the US Symptoms and Diagnosis Biomarkers.

+ High CJD infectivity remains after the prion protein is destroyed By Sylvester Gates.

Martine Bruley Rosset UMR S 938 INSERM Hôpital St Antoine Paris France

(Bovine spongiform encephalopathy)

Disease Transmission and Species Barrier

KEY CONCEPT Infections can be caused in several ways.

KEY CONCEPT Infections can be caused in several ways.

بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية

KEY CONCEPT Infections can be caused in several ways.

Nat. Rev. Neurol. doi: /nrneurol

Volume 134, Issue 5, Pages (September 2008)

KEY CONCEPT Infections can be caused in several ways.

Western blot analysis of skin tissue from CJD and non-CJD patients

KEY CONCEPT Infections can be caused in several ways.

Presentation transcript:

Founders With the support of

2 Letters of intent  Individual quotation, then selection by the SAB Validation by the Bureau  Full Application  Individual quotation, then selection by the SAB Proposal to the bureau  Selection and validation by Executive Comittee Selection process

3 Selected Projects Comparison of bioassay, Scrapie Cell- Assay and Protein Misfolding Cycle Assay performances for detection of endogenous Prion in sheep blood Principal Investigator: O. Andreoletti (INRA-ENVT, Toulouse, France)

4 Selected Projects Probing the chemistry and conformational change underlying autocatalytic self- propagation of misfolded prion protein Principal Investigator: M. Beekes (Robert Koch Institute, Berlin, Germany)

5 Selected Projects Optimisation, evaluation and validation of a PMCA-based confirmatory screening assay to detect prions in human blood. A French and British Collaborative Study Principal Investigators: J. Coste (EFS-PM, Montpellier, France) M. Jones (SNBTS, Edinburgh, UK)

6 Selected Projects Assessment of prion infectivity in blood in primate and sheep models, and evaluation of removal processes (extension 2009) Principal Investigator: D. Dernis (EFS-Nord, Lille, France)

7 Selected Projects Infectivity titrations of blood components from chimpanzees infected with the agent of Gerstmann-Sträussler-Scheinker Syndrome in mice and comparison of sensitivity of mouse bioassays Principal Investigator: L. Gregori (FDA, USA)

8 Selected Projects Evaluation of cold atmospheric plasma to decontaminate surgical instrument surfaces and eliminate prion infectivity Principal Investigators: C. W. Keevil (Southampton University, UK) R. Hervé (Southampton University, UK)

9 Selected Projects An assessment of the relevancy of sheep and mice animal model for blood safety investigation Principal Investigator: C. Lacroux (INRA-ENVT, Toulouse, France)

10 Selected Projects Detection of PrPSc (a biomarker for TSE infection) in blood using QUIC shake technology: validation of in vitro studies with infectivity models Principal Investigators: J. C. Manson (The Roslin Institute, UK) S. MacCutcheon (The Roslin Institute, UK)

11 Selected Projects Elucidation of the misfolding process… Insights into a preamyloid state by selectively trapping prion proteins in oligomeric forms Principal Investigator: J. Torrent (INSERM, Montpellier, France)

12 Selected Projects Risk assessment of Insoluble PrP from normal human brains Principal Investigator: W.Q. Zou (Case Western Reserve University, Cleveland, USA)